- Tetracaine
-
- $1.00 / 1kg
-
2026-01-20
- CAS:94-24-6
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 10 tons
- Tetracaine
-
- $5.00/ KG
-
2026-01-20
- CAS:94-24-6
- Min. Order: 1KG
- Purity: 99% hplc
- Supply Ability: 500TONS
- Tetracaine
-
- $5.00/ KG
-
2026-01-20
- CAS:94-24-6
- Min. Order: 1KG
- Purity: 99% hplc
- Supply Ability: 500TONS
|
| Product Name: | Tetracaine | | Synonyms: | 2-(Dimethylamino)ethyl 4-(butylamino)benzoate;2-(Dimethylamino)ethyl p-(butylamino)benzoate;2-Dimethylaminoethylester kyseliny p-butylaminobenzoove;2-dimethylaminoethylesterkyselinyp-butylaminobenzoove;2-dimethylaminoethylp-butylaminobenzoate;4-(butylamino)-benzoicaci2-(dimethylamino)ethylester;amethocaine;Anetain | | CAS: | 94-24-6 | | MF: | C15H24N2O2 | | MW: | 264.36 | | EINECS: | 202-316-6 | | Product Categories: | Pharmaceutical Intermediates;medical intermediate;API;94-24-6 | | Mol File: | 94-24-6.mol |  |
| | Tetracaine Chemical Properties |
| Melting point | 41.0 to 45.0 °C | | Boiling point | 407.59°C (rough estimate) | | density | 1.0200 (rough estimate) | | refractive index | 1.5800 (estimate) | | storage temp. | 2-8°C | | solubility | soluble in Methanol | | pka | pKa 8.33±0.03(H2O
t = 20.0
I = 0.10 (KCl)) (Uncertain) | | form | powder to crystal | | color | White to Almost white | | Water Solubility | 156mg/L(temperature not stated) | | Major Application | pharmaceutical | | InChI | InChI=1S/C15H24N2O2/c1-4-5-10-16-14-8-6-13(7-9-14)15(18)19-12-11-17(2)3/h6-9,16H,4-5,10-12H2,1-3H3 | | InChIKey | GKCBAIGFKIBETG-UHFFFAOYSA-N | | SMILES | C(OCCN(C)C)(=O)C1=CC=C(NCCCC)C=C1 | | LogP | 3.510 | | CAS DataBase Reference | 94-24-6(CAS DataBase Reference) | | NIST Chemistry Reference | Tetracaine(94-24-6) |
| Hazard Codes | Xn,Xi | | Risk Statements | 22-40-42/43-43 | | Safety Statements | 22-36/37 | | RIDADR | UN 2811 | | WGK Germany | 3 | | RTECS | DG4725000 | | HazardClass | 6.1 | | PackingGroup | III | | HS Code | 29224999 | | Storage Class | 6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | | Hazard Classifications | Acute Tox. 3 Oral
Carc. 2
Skin Sens. 1 |
| | Tetracaine Usage And Synthesis |
| Uses | Tetracaine is used in assessing the potential for drug-nanoparticle surface interactions to improve drug penetration into the skin. | | Description | Tetracaine is a local anesthetic or numbing medicine that is used to numb the throat, eyes, or nose. Normally, the drug is administered before starting a surgery to decrease pain from the procedure. Tetracaine is applied to the eyes 30 minutes before the start of an intravenous and its effects can last up to 15 minutes.
| | Mechanism of Action | Tetracaine acts by blocking the nerve systems. It does this by blocking the sodium ion channels needed for the conduction and initiation of neural impulses, thereby affecting the local anesthesia. Tetracaine acts by altering the function of calcium release channels that controls the release of calcium frim intracellular cells.
| | Precautions | No studies have revealed whether the medicine can affect an unborn child; however, it is important to inform the doctor if pregnant while using it.
Informing the doctor is paramount if breastfeeding a baby, as no known research has illustrated whether tetracaine can pass into breast milk or harm a nursing baby.
To make tetracaine safe, it is important to inform the doctor if one has a history of spinal or brain injury, heart diseases, eye problems, a blood vessel disorder, open sores, skin injury in the area where the medicine will be applied.
Tetracaine should never be orally taken since it is typically designed for use on the skin only. If the medicine gets in the mouth, nose, vagina, or rectum, rinse with water.
| | Application | Tetracaine topical (for the skin) is used to numb various body parts before a surgical procedure or a medical test. Conversely, tetracaine ophthalmic drops are used as local anesthetic for the eyes.
| | Dosage | Always follow all direction on the prescription label. Do not use the medicine in smaller or larger amounts or for longer than recommended.
| | Side Effects | Seek emergency medical advice in case of any of the following allergic reactions: difficult breathing, hives, swelling of the throat, tongue, lips, or face. Stop using the drug and call the physician if one has severe burning, swelling, stinging, or other irritation of the treated skin. Other alarming symptoms include eye watering, irritation, and increased sensitivity to light.
Common side effects include burning, stinging, or itching at the point of application of the medicine; numbness in places where tetracaine has been accidentally applied or skin redness or tenderness.
Nonclinical Toxicology
Studies conducted to reveal the genotoxicity of tetracaine have not indicated its mutagenesis, carcinogenicity, or impairment of fertility.
| | Chemical Properties | White or light-yellow, waxy solid. Very slightly soluble in water; soluble in
alcohol, ether, benzene, chloroform. | | Uses | analgesic | | Uses | Tetracaine has been used as an anesthetic and to lower the glucose synthesis in upper small intestinal infusions. It has also been used to inhibit ryanodine receptors (RyRs) in rats. | | Uses | Topical ophthalmic anesthetic; used for spinal anesthesia | | Uses | Tetracaine, also known as amethocaine, is the most potent and lipidsoluble
ester local anaesthetic and has significant potential for toxicity if
used systemically. It is commonly used as a 4% gel for topical application to
decrease the pain from venous puncture or cannulation. | | Definition | ChEBI: A benzoate ester in which 4-N-butylbenzoic acid and 2-(dimethylamino)ethanol have combined to form the ester bond; a local ester anaesthetic (ester caine) used for surface and spinal anaesthesia. | | Biological Functions | Tetracaine hydrochloride (Pontocaine) is an ester of
PABA that is an effective topical local anesthetic agent and also is quite commonly used for spinal (subarachnoid)
anesthesia. Epinephrine is frequently added to
prolong the anesthesia.Tetracaine is considerably more
potent and more toxic than procaine and cocaine. It
has approximately a 5-minute onset and 2 to 3 hours of
action. | | General Description | Tetracaine was developed to address the low potency andshort duration of action of procaine and chloroprocaine. The addition of the butyl side chain on the para nitrogen increasesthe lipid solubility of the drug and enhances the topical potencyof tetracaine. The plasma half-life is 120 to 150 seconds.Topically applied tetracaine to unbroken skin requires 30 to 45minutes to confer topical anesthesia. Tetracaine 4% gel is superiorthan eutectic mixture with lidocaine (EMLA) (an emulsionof lidocaine and prilocaine) in preventing pain associatedwith needle procedures in children. Tetracaine metabolism issimilar to procaine ester metabolism yielding parabutylaminobenzoicacid and dimethylaminoethanol and conjugatesexcreted in the urine. The pKa of the dimethylated nitrogen is8.4 and tetracaine is formulated as a hydrochloride salt with apH of 3.5 to 6.0. The increased absorption from topical siteshas resulted in reported toxicity. Overdoses of tetracaine mayproduce central nervous system (CNS) toxicity and seizure activitywith fatalities from circulatory depression reported.No selective cardiac toxicity is seen with tetracaine althoughhypotension has been reported. Tetracaine is employed for infiltrationanesthesia, spinal anesthesia, or topical use. | | Biochem/physiol Actions | Tetracaine also refers as 4-(Butylamino)benzoic acid 2-(dimethylamino)ethyl ester interfere with calcium movement in muscle and non-muscle cells and can inhibit potassium-induced as well as caffeine-induced shortening of outer hair cells (OHC′s). But, the product can′t inhibit electrically-induced shortening of OHC′s.The product can also stimulate caspase activation and inhibits pro-survival signalling pathways which in turn induce human renal cell apoptosis. | | Synthesis | General procedure for the synthesis of 2-(dimethylamino)ethyl 4-(butylamino)benzoate from bromobutane and 2-(dimethylamino)ethyl 4-aminobenzoate: 5.0 g of p-aminobenzoic acid-2-dimethylaminoethyl ester (0.024 mol), 3.3 g of 1-bromonobutane (0.024 mol), 10.0 g of K2CO3 (0.072 mol) and 50 mL of N,N-dimethylformamide were added to a 100 mL three-neck flask. ) and 50 mL of N,N-dimethylformamide were added to a 100 mL three-neck flask. The mixture was stirred and heated to 50 °C, keeping the reaction temperature at 50 °C. After 5 hours of reaction, the heating was stopped and the reaction system was allowed to cool to room temperature. The reaction mixture was filtered and the filtrate was extracted with 50 mL of dichloromethane. The aqueous phase was extracted again with 50 mL of dichloromethane. The organic phases were combined and 5.3 g of white solid product was obtained in 82.8% yield after evaporating the solvent. | | Veterinary Drugs and Treatments | Tetracaine is more irritating than proparacaine but is sometimes
used in veterinary medicine. It is indicated to produce local anesthesia
of short duration for ophthalmic procedures including measurement
of intraocular pressure (tonometry), removal of foreign
bodies and sutures, and conjunctival and corneal scraping in diagnosis
and gonioscopy. Tetracaine is also indicated to produce local
anesthesia prior to surgical procedures in humans such as cataract
extraction and pterygium excision, usually as an adjunct to locally
injected anesthetics. Ophthalmic solutions used for intraocular
procedures should be preservative-free. Preservatives may cause
damage to the corneal epithelium if a significant quantity of solution
enters the eye through the incision. | | References | [1] Patent: CN106518697, 2017, A. Location in patent: Paragraph 0014
[2] Patent: US1889645, 1932,
[3] Fortschr. Teerfarbenfabr. Verw. Industriezweige, vol. 19, p. 1536 |
| | Tetracaine Preparation Products And Raw materials |
|